Skip to main content
. Author manuscript; available in PMC: 2023 Apr 1.
Published in final edited form as: Drug Deliv Transl Res. 2021 Apr 26;12(4):826–837. doi: 10.1007/s13346-021-00987-6

Fig. 3.

Fig. 3

(a) Schematics showing the timeline for pharmacokinetic and efficacy studies in pigmented Brown Norway rats with once weekly dosing (arrows) of SunitiGel. A total of three doses were given in the pharmacokinetic study, and tissues were collected at 1, 4, and 7 d after the last dose. For efficacy experiments, optic nerve crush occurred one day after the second dose, and tissues were collected for qPCR and RGC counting one day after the fourth dose. (b) Combined levels of sunitinib and N-desethyl sunitinib in the retina, Ch/RPE, and vitreous (n = 5 – 6) over time after the third weekly dose. Data are shown as mean ± SD. (c) Increased gene expression level of γ-synuclein and βIII-tubulin was observed in rats (n = 4 – 5) receiving SunitiGel treatment compared to Crush Only. Data are shown as mean ± SD. (d) RGC counting in whole retinal flat mounts (n = 11 – 12) confirms increased survival with SunitiGel treatment. Data are shown as mean ± SD